Cogentix Medical Inc (NASDAQ:CGNT) Shorts Rose By 317.76%

April 20, 2018 - By Sarah North

Cogentix Medical, Inc. (NASDAQ:CGNT) Corporate Logo

It was reported an increase on Cogentix Medical Inc (NASDAQ:CGNT)’s shorted shares with 317.76%. In April was issued CGNT’s total 235,200 shorted shares by FINRA. The up change of 317.76% from 56,300 shares was reported. With Average volume 329,500, CGNT’s former position will take 1 days to restore. 1.24% is Cogentix Medical Inc float short.

CGNT reached $3.85 during the last trading session after $0.01 change.Currently Cogentix Medical, Inc. is uptrending after 110.93% change in last April 20, 2017. CGNT has 78,908 shares volume. The stock outperformed the S&P500 by 99.38%.

Cogentix Medical, Inc., a medical device company, designs, develops, makes, and markets fiberoptic and video endoscopy products under the PrimeSight brand worldwide.The firm is valued at $234.56 million. The firm offers endoscopes, such as cystoscopes, laryngoscopes, transnasal esophagoscopes, and bronchoscopes for medical use; and borescopes for industrial use, as well as digital processing units for medical use.Last it reported negative earnings. It also provides EndoSheath Protective Barrier, a sterile, single-use microbial barrier for use with flexible endoscopes.

Cogentix Medical, Inc. (NASDAQ:CGNT) Ratings Coverage

In total 2 analysts cover Cogentix Medical (NASDAQ:CGNT). “Buy” rating has 0, “Sell” are 0, while 2 are “Hold”. 0 are bullish. With $4.75 highest and $3.8500 lowest [Target] Cogentix Medical has $4.30 average [Target] or 11.69% above the current ($3.85) price. 4 are the (NASDAQ:CGNT)’s analyst reports since November 8, 2017 according to StockzIntelligence Inc. In Friday, March 23 report Roth Capital downgraded it to “Hold” rating and $3.8500 target. In Tuesday, March 13 report Aegis Capital downgraded the stock to “Hold” rating. On Wednesday, November 8 the stock of Cogentix Medical, Inc. (NASDAQ:CGNT) has “Buy” rating given by Roth Capital.

Cogentix Medical, Inc. (NASDAQ:CGNT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: